Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice.

Norton TD, Zhen A, Tada T, Kim J, Kitchen S, Landau NR.

Mol Ther. 2019 May 8;27(5):960-973. doi: 10.1016/j.ymthe.2019.03.008. Epub 2019 Mar 15.

PMID:
30962161
2.

Toll-like receptor agonist R848 blocks Zika virus replication by inducing the antiviral protein viperin.

Vanwalscappel B, Tada T, Landau NR.

Virology. 2018 Sep;522:199-208. doi: 10.1016/j.virol.2018.07.014. Epub 2018 Jul 20.

3.

DNA damage induces a SAMHD1-mediated block to the infection of macrophages by HIV-1.

Jáuregui P, Landau NR.

Sci Rep. 2018 Mar 7;8(1):4153. doi: 10.1038/s41598-018-22432-4.

4.

Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5.

Tam K, Schultz M, Reyes-Robles T, Vanwalscappel B, Horton J, Alonzo F 3rd, Wu B, Landau NR, Torres VJ.

MBio. 2016 Dec 13;7(6). pii: e02024-16. doi: 10.1128/mBio.02024-16.

5.

A Highly Active Isoform of Lentivirus Restriction Factor SAMHD1 in Mouse.

Bloch N, Gläsker S, Sitaram P, Hofmann H, Shepard CN, Schultz ML, Kim B, Landau NR.

J Biol Chem. 2017 Jan 20;292(3):1068-1080. doi: 10.1074/jbc.M116.743740. Epub 2016 Dec 5.

6.

TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes.

Hofmann H, Vanwalscappel B, Bloch N, Landau NR.

Retrovirology. 2016 Dec 1;13(1):83.

7.

Intrinsic host restrictions to HIV-1 and mechanisms of viral escape.

Simon V, Bloch N, Landau NR.

Nat Immunol. 2015 Jun;16(6):546-53. doi: 10.1038/ni.3156. Review.

PMID:
25988886
8.

Degradation of SAMHD1 by Vpx Is Independent of Uncoating.

Jáuregui P, Logue EC, Schultz ML, Fung S, Landau NR.

J Virol. 2015 May;89(10):5701-13. doi: 10.1128/JVI.03575-14. Epub 2015 Mar 11.

9.

Vpx-containing dendritic cell vaccine induces CTLs and reactivates latent HIV-1 in vitro.

Norton TD, Miller EA, Bhardwaj N, Landau NR.

Gene Ther. 2015 Mar;22(3):227-36. doi: 10.1038/gt.2014.117. Epub 2015 Jan 8.

10.

Interactions with DCAF1 and DDB1 in the CRL4 E3 ubiquitin ligase are required for Vpr-mediated G2 arrest.

Hakata Y, Miyazawa M, Landau NR.

Virol J. 2014 Jun 9;11:108. doi: 10.1186/1743-422X-11-108.

11.

SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors.

Huber AD, Michailidis E, Schultz ML, Ong YT, Bloch N, Puray-Chavez MN, Leslie MD, Ji J, Lucas AD, Kirby KA, Landau NR, Sarafianos SG.

Antimicrob Agents Chemother. 2014 Aug;58(8):4915-9. doi: 10.1128/AAC.02745-14. Epub 2014 May 27.

12.

A DNA sequence recognition loop on APOBEC3A controls substrate specificity.

Logue EC, Bloch N, Dhuey E, Zhang R, Cao P, Herate C, Chauveau L, Hubbard SR, Landau NR.

PLoS One. 2014 May 14;9(5):e97062. doi: 10.1371/journal.pone.0097062. eCollection 2014.

13.

The innate immune response to HIV-1: to sense or not to sense.

Landau NR.

DNA Cell Biol. 2014 May;33(5):271-4. doi: 10.1089/dna.2014.2378. Epub 2014 Mar 25. Review.

14.

SAMHD1 restricts HIV-1 replication and regulates interferon production in mouse myeloid cells.

Zhang R, Bloch N, Nguyen LA, Kim B, Landau NR.

PLoS One. 2014 Feb 19;9(2):e89558. doi: 10.1371/journal.pone.0089558. eCollection 2014.

15.

Inhibition of CUL4A Neddylation causes a reversible block to SAMHD1-mediated restriction of HIV-1.

Hofmann H, Norton TD, Schultz ML, Polsky SB, Sunseri N, Landau NR.

J Virol. 2013 Nov;87(21):11741-50. doi: 10.1128/JVI.02002-13. Epub 2013 Aug 28.

16.

HIV type 1 infection of plasmacytoid and myeloid dendritic cells is restricted by high levels of SAMHD1 and cannot be counteracted by Vpx.

Bloch N, O'Brien M, Norton TD, Polsky SB, Bhardwaj N, Landau NR.

AIDS Res Hum Retroviruses. 2014 Feb;30(2):195-203. doi: 10.1089/AID.2013.0119. Epub 2013 Sep 4.

17.

Restriction of diverse retroviruses by SAMHD1.

Gramberg T, Kahle T, Bloch N, Wittmann S, Müllers E, Daddacha W, Hofmann H, Kim B, Lindemann D, Landau NR.

Retrovirology. 2013 Mar 5;10:26. doi: 10.1186/1742-4690-10-26.

18.

CCR5 is a receptor for Staphylococcus aureus leukotoxin ED.

Alonzo F 3rd, Kozhaya L, Rawlings SA, Reyes-Robles T, DuMont AL, Myszka DG, Landau NR, Unutmaz D, Torres VJ.

Nature. 2013 Jan 3;493(7430):51-5. doi: 10.1038/nature11724. Epub 2012 Dec 12.

19.

The Vpx lentiviral accessory protein targets SAMHD1 for degradation in the nucleus.

Hofmann H, Logue EC, Bloch N, Daddacha W, Polsky SB, Schultz ML, Kim B, Landau NR.

J Virol. 2012 Dec;86(23):12552-60. doi: 10.1128/JVI.01657-12. Epub 2012 Sep 12.

20.

SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells.

Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, Schenkova K, Ambiel I, Wabnitz G, Gramberg T, Panitz S, Flory E, Landau NR, Sertel S, Rutsch F, Lasitschka F, Kim B, König R, Fackler OT, Keppler OT.

Nat Med. 2012 Nov;18(11):1682-7. doi: 10.1038/nm.2964.

21.

Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein.

Bobadilla S, Sunseri N, Landau NR.

Gene Ther. 2013 May;20(5):514-20. doi: 10.1038/gt.2012.61. Epub 2012 Aug 16.

22.

SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates.

Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, Pancino G, Priet S, Canard B, Laguette N, Benkirane M, Transy C, Landau NR, Kim B, Margottin-Goguet F.

Nat Immunol. 2012 Feb 12;13(3):223-228. doi: 10.1038/ni.2236. Erratum in: Nat Immunol. 2013 Aug;14(8):877.

23.

The cargo-binding domain of transportin 3 is required for lentivirus nuclear import.

Logue EC, Taylor KT, Goff PH, Landau NR.

J Virol. 2011 Dec;85(24):12950-61. doi: 10.1128/JVI.05384-11. Epub 2011 Oct 5.

24.

Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells.

Sunseri N, O'Brien M, Bhardwaj N, Landau NR.

J Virol. 2011 Jul;85(13):6263-74. doi: 10.1128/JVI.00346-11. Epub 2011 Apr 20.

25.

Evidence for an activation domain at the amino terminus of simian immunodeficiency virus Vpx.

Gramberg T, Sunseri N, Landau NR.

J Virol. 2010 Feb;84(3):1387-96. doi: 10.1128/JVI.01437-09. Epub 2009 Nov 18.

26.

Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase.

Narvaiza I, Linfesty DC, Greener BN, Hakata Y, Pintel DJ, Logue E, Landau NR, Weitzman MD.

PLoS Pathog. 2009 May;5(5):e1000439. doi: 10.1371/journal.ppat.1000439. Epub 2009 May 22.

27.

Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent.

Browne EP, Allers C, Landau NR.

Virology. 2009 May 10;387(2):313-21. doi: 10.1016/j.virol.2009.02.026. Epub 2009 Mar 21.

28.

Accessories to the crime: recent advances in HIV accessory protein biology.

Gramberg T, Sunseri N, Landau NR.

Curr HIV/AIDS Rep. 2009 Feb;6(1):36-42. Review.

29.

Guidelines for naming nonprimate APOBEC3 genes and proteins.

LaRue RS, Andrésdóttir V, Blanchard Y, Conticello SG, Derse D, Emerman M, Greene WC, Jónsson SR, Landau NR, Löchelt M, Malik HS, Malim MH, Münk C, O'Brien SJ, Pathak VK, Strebel K, Wain-Hobson S, Yu XF, Yuhki N, Harris RS.

J Virol. 2009 Jan;83(2):494-7. doi: 10.1128/JVI.01976-08. Epub 2008 Nov 5. No abstract available.

30.

HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1.

Schröfelbauer B, Hakata Y, Landau NR.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4130-5. Epub 2007 Feb 28.

31.

Analysis of Vif-induced APOBEC3G degradation using an alpha-complementation assay.

Fang L, Landau NR.

Virology. 2007 Mar 1;359(1):162-9. Epub 2006 Oct 17.

32.

Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains.

Hakata Y, Landau NR.

J Biol Chem. 2006 Dec 1;281(48):36624-31. Epub 2006 Oct 4.

33.
34.

APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.

Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, Landau NR, Weitzman MD.

Curr Biol. 2006 Mar 7;16(5):480-5.

35.

Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.

Schröfelbauer B, Yu Q, Zeitlin SG, Landau NR.

J Virol. 2005 Sep;79(17):10978-87.

36.

Complementary function of the two catalytic domains of APOBEC3G.

Navarro F, Bollman B, Chen H, König R, Yu Q, Chiles K, Landau NR.

Virology. 2005 Mar 15;333(2):374-86.

37.

APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.

Yu Q, Chen D, König R, Mariani R, Unutmaz D, Landau NR.

J Biol Chem. 2004 Dec 17;279(51):53379-86. Epub 2004 Oct 4.

38.

Recent insights into HIV-1 Vif.

Navarro F, Landau NR.

Curr Opin Immunol. 2004 Aug;16(4):477-82. Review.

PMID:
15245742
39.

New insights into the role of Vif in HIV-1 replication.

Schröfelbauer B, Yu Q, Landau NR.

AIDS Rev. 2004 Jan-Mar;6(1):34-9. Review.

PMID:
15168739
40.

Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.

Yu Q, König R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR.

Nat Struct Mol Biol. 2004 May;11(5):435-42. Epub 2004 Apr 18.

PMID:
15098018
41.

Alpha-complementation assay for HIV envelope glycoprotein-mediated fusion.

Holland AU, Munk C, Lucero GR, Nguyen LD, Landau NR.

Virology. 2004 Feb 20;319(2):343-52.

42.

A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).

Schröfelbauer B, Chen D, Landau NR.

Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3927-32. Epub 2004 Feb 20.

43.

Production and use of HIV-1 luciferase reporter viruses.

Münk C, Landau NR.

Curr Protoc Pharmacol. 2003 Nov;Chapter 12:Unit12.5. doi: 10.1002/0471141755.ph1205s22.

PMID:
21956804
44.

The theta-defensin, retrocyclin, inhibits HIV-1 entry.

Münk C, Wei G, Yang OO, Waring AJ, Wang W, Hong T, Lehrer RI, Landau NR, Cole AM.

AIDS Res Hum Retroviruses. 2003 Oct;19(10):875-81.

PMID:
14585219
45.

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR.

Cell. 2003 Jul 11;114(1):21-31.

46.

Inhibition of HIV-1 infection by a CCR5-binding cyclophilin from Toxoplasma gondii.

Golding H, Aliberti J, King LR, Manischewitz J, Andersen J, Valenzuela J, Landau NR, Sher A.

Blood. 2003 Nov 1;102(9):3280-6. Epub 2003 Jul 10.

47.

HIV-1 Vpr activates cell cycle inhibitor p21/Waf1/Cip1: a potential mechanism of G2/M cell cycle arrest.

Chowdhury IH, Wang XF, Landau NR, Robb ML, Polonis VR, Birx DL, Kim JH.

Virology. 2003 Jan 20;305(2):371-7.

48.

Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells.

Kootstra NA, Munk C, Tonnu N, Landau NR, Verma IM.

Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1298-303. Epub 2003 Jan 23.

49.

A dominant block to HIV-1 replication at reverse transcription in simian cells.

Münk C, Brandt SM, Lucero G, Landau NR.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13843-8. Epub 2002 Oct 4.

50.

Vpr- and Nef-dependent induction of RANTES/CCL5 in microglial cells.

Si Q, Kim MO, Zhao ML, Landau NR, Goldstein H, Lee S.

Virology. 2002 Sep 30;301(2):342-53.

Supplemental Content

Loading ...
Support Center